// App-Quantinova.ai

7013 : 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Javier Pinilla-Ibarz

  • Philipp D. Le Coutre

  • Ronald Paquette

  • Charles Chuah

  • Franck E. Nicolini

  • Jane Apperley

  • Hanna Jean Khoury

  • Moshe Talpaz

  • Michele Baccarani

  • Stephanie Lustgarten

  • Frank G. Haluska

  • Francois Guilhot

  • Michael W.N. Deininger

  • Andreas Hochhaus

  • Timothy P Hughes

  • Neil P. Shah

  • Hagop M. Kantarjian

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Ronald Reagan UCLA Medical Center, University of California, Los Angeles, CA

  • Singapore General Hospital and Duke-National University of Singapore Graduate Medical School, Singapore, Singapore

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Comprehensive Cancer Center, University of Michigan, Grass Lake, MI

  • S. Orsola-Malpighi University Hospital, Bologna, Italy

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • Inserm CIC 1402, CHU de Poitiers, Poitiers, France

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Essen University Hospital, Essen, Germany

  • Institute of Medicine and Veterinary Science, Adelaide, Australia

  • University of California, San Francisco, San Francisco, CA

Locations

  • Italy

  • Singapore

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • ARIAD Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Nilotinib

  • Ponatinib

  • dasatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01207440

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved